Business
DECN in Major Revenue Move Decides to Include New GenAccord! Product Line in its Upcoming Strategic Agreement at the Request of Strategic Partner
DECN in Major Revenue Move Decides to Include New GenAccord! Product Line in its Upcoming Strategic Agreement at the Request of Strategic Partner.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"COMPANY TO DISCUSS THIS BUSINESS MOVE IN FURTHER DETAIL EARLY NEXT WEEK, SHORTLY THEREAFTER DECN WILL POST FORECASTS ON ITS WEB SITE LOS ANGELES, CA / ACCESSWIRE / December 12, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International markets, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.DECN announces today that have accepted a gesture from our proposed partner to include our GenAccord! meter and test strips, and the GenAccord! MS (multi-user system meter and test strips) as a part of the license agreement, now nearing completion. The two GenAccord! product lines will be independently targeted to uninsured and under-insured diabetics, and separately to chain nursing homes and clinics/urgent care locations.Keith Berman, CEO of DECN commented, "We have definitely decided to have our Taiwanese contract manufacturer to package for us two distinct FDA cleared systems, both systems using the same version test strips (vial packaged, and individually wrapped strips). We are in the process of completing the various forecasts for these three business units and will discuss everything further next week, inclusive of posting our forecasts, which will have already been signed off on by our partners. The direct to patient model will be implemented on Amazon, Walmart and over 1000 other on-line services in early 1Q 2020." Mr. Berman concluded, "We were happy to see that when we asked our partner to provide a "cocktail napkin" forecast and guaranteed minimum purchases for GenAccord! it became clear to us that...